Barinthus Biotherapeutics Pl (BRNS) 13F Ownership Report (Q2 2026)

BRNS ranks #9090 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

BRNS is a top-conviction position for DC Funds, LP — at 33.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Rangeley Capital, LLC has added to its BRNS position for two straight quarters, increasing it by $63.1K to reach $122.2K today.

HSG Holding Ltd has trimmed its BRNS position for two straight quarters, cutting it by $41.3M while still holding $937.5K.

BRNS reported a net loss of $41.8M over the trailing twelve months.

• Not yet profitable — net loss of $41.8M over the trailing twelve months
• Revenue declined 0.0% year over year
• Net income improved year over year, from -$69.4M to -$41.8M
• Operating cash flow was negative, using $48.0M in cash
• Current ratio of 7.76x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.32x equity — within a conventional range